UCLA

Running trials

• Recruiting

  Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

  NCT07070466· Phase 2· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Active, not recruiting

  A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  NCT06561685· Phase 1· Source

• Recruiting

  Starting Technology in At Risk Type 1 Diabetes Study

  NCT06453928· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Source

• Recruiting

  Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT05379985· Phase 1/2· Source

• Active, not recruiting

  HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

  NCT04676477· Phase 1· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Gastric and esophageal cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Pancreatic cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

  NCT04484142· Phase 2· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Source